In this edition, obesity linked to adverse outcomes among AYAs; pirtobrutinib produces high response rates; CDC study reveals overall increase in pediatric cancer incidence and more. Read the full coverage here:

Overweight, obesity linked to adverse outcomes among AYAs treated for leukemia

Pirtobrutinib produces high response rates in heavily pretreated CLL, SLL

CDC study reveals overall increase in pediatric cancer incidence over 16 years

Cancers with high incidence among racial/ethnic minorities receive less research funding

Women more likely to experience severe toxicity from cancer treatment

References:

Haghighat S, et al. J Natl Cancer Inst. 2023;doi:10.1093/jnci/djad097.

Mato AR, et al. N Engl J Med. 2023;doi:10.1056/NEJMoa2300696.

Shimony S, et al. Blood Adv. 2023;doi:10.1182/bloodadvances.2023009976.

Siegel DA, et al. J Natl Cancer Inst. 2023;doi:10.1093/jnci/djad115.

Unger JM, et al. Abstract SY43-03. Presented at American Association for Cancer Research Annual Meeting; April 14-19, 2023; Orlando.